Skip to main content

Table 1 Clinical characteristics of Responders and Partial-/Non-Responders at baseline and under treatment with Anti-T2 biological therapy

From: Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study

Variable

Baseline

Under treatment

Mean of difference

Percentage change (%)

P- Value

Responders (n = 13)

Age (years)

59.4 ± 9.8

Sex (f/m)

(9/4)

BMI (kg/m2)

26.4 ± 6.1

Blood eosinophil count (/μL)

620.8 ± 378.8

97.7 ± 160.7

− 523.1

− 84

 < 0.01

FEV1(l)

2.1 ± 0.88

2.6 ± 1.1

+ 0.520

+ 24

 < 0.01

FEV%

75.8 ± 21.7%

96.2 ± 18.1%

+ 20.4%

+ 26

 < 0.01

FEF25–75 (l/s)

1.03 ± 0.77

1.64 ± 1.06

+ 0.61

+ 59

 < 0.01

RV%

153 ± 21%

121 ± 20%

− 32%

− 21

0.02

RV/TLC

48 ± 9%

38 ± 9%

− 10%

− 21

0.02

FDR (KPa/l/s)

0.26 ± 0.20

0.12 ± 0.16

− 0.13

− 50

 < 0.01

FDR%pred

270% ± 151

168% ± 85

− 103%

− 37

0.02

FeNo(ppb)

56.1 ± 26.4

40.8 ± 27.5

− 15.31

− 27

 < 0.01

ACT score

14.2 ± 5.3

19.8 ± 4.7

+ 5.5

+ 39

 < 0.01

Number of exacerbations

5.5 ± 3.1

1.1 ± 1.2

− 4.4

− 80

 < 0.01

OSC dose (mg)

5.9 ± 5

0.4 ± 0.9

− 5.5

− 93

 < 0.01

Partial-/non-responders (n = 7)

Age (years)

60.86 ± 8.30

Sex (f/m)

(3/4)

BMI (kg/m2)

29.86 ± 3.0

Blood eosinophil count (/μL)

474.3 ± 420.1

200.0 ± 355.9

− 274.2

− 58

 > 0.05

FEV1 (l)

2.0 ± 0.58

1.7 ± 0.41

− 0.343

− 17

 > 0.05

FEV%

77.6 ± 22.7%

67.1 ± 20.5%

− 10.4%

− 13

 > 0.05

FEF25–75 (l/s)

1.13 ± 0.72

0.81 ± 0.45

− 0.32

− 28

 > 0.05

RV%

140 ± 29%

150 ± 29%

+ 10%

+ 7

 > 0.05

RV/TLC

45 ± 8%

50 ± 3%

+ 5%

+ 11

 > 0.05

FDR (KPa/l/s)

0.13 ± 0.11

0.23 ± 0.17

+ 0.10

+ 76

 > 0.05

FDR%pred

146% ± 76%

209% ± 151%

+ 63%

+ 43

 > 0.05

FeNo (ppb)

41.4 ± 43.7

57.9 ± 38.7

+ 16.4

+ 39

 > 0.05

ACT score

17.9 ± 4.9

17.3 ± 3.6

− 0.571

− 3

 > 0.05

Number of exacerbations

4.1 ± 2.9

3.0 ± 2.0

− 1.14

− 27

 > 0.05

OSC dose (mg)

7.2 ± 5.1

4.7 ± 3.7

− 2.6

36

 > 0.05

  1. Values at baseline and under treatment, as well as means of differences (+ or -) are presented as means ± standard deviations
  2. Absolute blood eosinophils (cells/µl), FEV1: forced expiratory volume in the 1 s (l), FEF25-75: forced expiratory flow between 25 and 75% of the forced vital capacity, RV: residual volume, TLC: total lung capacity, FDR (%): frequency dependence resistance (R5-20 kPa/l/s) and predicted values, FeNO: fractional exhaled nitric oxide (ppb), ACT: asthma control test score, number of exacerbations in the last 12 months, OCS: oral corticosteroid (mg)
  3. P values according to an appropriate test (t. test or Wilcoxon test). P-values in the last column represent test of baseline data vs. data under anti-T2 biological treatment within each of the two groups (responders vs. partial/non-responders). At baseline, clinical variables were also tested between groups and did not show any significant differences, except for FDR%pred (p = 0.038)
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us